Medtronic PLC (MDT)
Medtronic PLC (MDT) carries a ŷRobot AI score of 45 out of 100. The model's fair value estimate is $85.37, 17.0% below the last close of $102.88. The chart signal reads Sell.
| Metric | MDT |
|---|---|
| AI score | 45 / 100 |
| Chart signal | Sell |
| Fair value estimate | $85.37 |
| Upside to fair value | -17.0% |
| Previous close | $102.88 |
| P/E | 21.24 |
| Price / sales | 2.95 |
| Market cap | $129.97B |
| EPS | 4.07 |
| Revenue growth | 5.0% |
| 1-year price change | 1.3% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
Questions about MDT
Is MDT overvalued or undervalued right now?
As of Oct 2, 2026, ŷRobot's fair-value model estimates Medtronic PLC (MDT) at $85.37 against a last close of $102.88, implying 17.0% downside to the model's estimate.
Is MDT's chart signal bullish or bearish?
The chart-signal model classifies MDT as Neutral as of Nov 13, 2026, with a signal score of -0.12 on a -1 to 1 scale.
What is MDT's ŷRobot AI score?
MDT scores 45 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Nov 13, 2026.
Is MDT stock expensive on P/E and P/S?
MDT trades at 21.2 times earnings and 2.9 times sales as of Nov 13, 2026.
What does MDT's seasonal forecast show?
ŷRobot's seasonal forecast curve for MDT reads +0.4% at 30 days, +3.1% at 90 days, and +1.3% at one year as of Nov 13, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is MDT growing?
Medtronic PLC's revenue growth is +5.0% and free-cash-flow growth is +3.2% on the latest reported figures.
MDT chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.